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Amyloidosis is widely distributed in the animal 
kingdom. The clinical features of this disorder are 
a consequence of the destruction and replacement 
of vital organs by the extracellular deposition of a 
proteinaceous substance known as amyloid. This 
material has been recognized by its homogeneous 
eosinophilic appearance when viewed by light 
microscopy, and by its staining properties with 
alkaline Congo red and certain metachromatic 
dyes. Hence, it is not surprising that recent bio-
chemical and immunologic studies of amyloid 
substance have provided strong support for the 
clinical impression that amyloidosis may be a term 
that encompasses a variety of different disorders. 
Before discussing the nature of the cutaneous 
forms of amyloid, it seems appropriate to summa-
rize the characteristic features of the different 
types of amyloidosis and to discuss some of the 
properties of the amyloid substance in relation to 
possible pathogenetic mechanisms . 
Amyloidosis is relatively rare as a clinically 
significant diseas.e. Nevertheless, because of its 
varied manifestations, its frequent association 
with a number of diseases involving the immune 
system, and the deposition of amyloid as part of 
the aging process, amyloidosis has attracted the 
interest of clinicians , chemists, immunologists , 
and pathologists since its recognition 125 years 
ago. Progress has been hampered by difficulties in 
isolating the amyloid substance and by the fact 
that an almost infinite number of apparently 
dissimilar stimuli can induce its production. Two 
major observations during the last 15 years have 
advanced our understanding of the amyloid sub-
stance and have given us significant insights into 
some factors that may playa role in the pathogen-
esis of the disease. The first was the discovery, 
through the use of the electron microscope , that 
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the apparently homogeneous amyloid material 
consists of characteristic long fibrils. These have a 
diameter of 100 to 150 A and are made up of two 
longitudinal subunits or filaments 40-60 A in 
diameter separated by a clear space of 25 to 50 A 
[1-4]. The second was the isolation of the fibrils in 
a state of high purity, thereby allowing sophisti-
cated study of the constituent proteins [3,5], and 
the consequent demonstration of the existence of 
several different types of amyloid substance. 
Since it appears likely that the different clinical 
forms of amyloidosis may ultimately be shown to 
be associated with characteristic types of amyloid 
fibrils , it seems appropriate to describe briefly the 
more important clinical forms of amyloidosis 
before discussing the amyloid fibrils. 
CLASSIFI CATION 
The following major forms of amyloidosis are 
recognized: (1) primary amyloidosis and the type 
associated with plasma cell and lymphoid neo-
plasms, (2) secondary amyloidosis , (3) a variety of 
heredofamilial forms, (4) amyloidosis associated 
with aging, and (5) amyloidosis of certain endo-
crine organs . The diagnosis in all types can be 
suspected on the basis of the clinical and labora-
tory features but requires histologic documenta-
tion to be certain. In the event that an involved 
organ is not suitable for biopsy, a rectal or gingival 
biopsy is likely to yield positive results in over 90 % 
of the patients [6,7]. For optimal results , the tissue 
must be carefully stained with alkaline Congo red 
or certain metachromatic dyes, and should be 
properly studied by polarization microscopy when 
Congo red is used. The diagnostic value of specific 
fluorescent antisera remains to be determined [8]. 
The quantitation of certain serum proteins related 
to amyloid (see below) , while theoretically and 
potentially rewarding, has not proved useful due to 
a lack of specificity. It is generally possible to 
classify a particular patient on the basis of the 
presence or absence of other associated diseases 
and the tissue distribution of the amyloid deposits , 
together with careful imm unochemical analyses of 
serum and urine. However, it is now widely appre-
ciated that clinical manifestations and organ local-
ization are often insufficient by themselves to 
achieve this goal in view of the frequent occurrence 
of deposits in atypical sites [9-11]. It seems likely 
that in time a precise classification will be based 





The most common and perhaps the most "typi-
cal" form of amyloidosis is that which accompanies 
many chronic illnesses and is therefore called the 
"secondary form" of amyloidosis. In the past, 
suppurative conditions such as osteomyelitis, tu-
berculosis, and bronchiectasis headed the list of 
associated diseases; presently, this type of amyloi-
dosis is more often encountered in patients with 
paraplegia and other chronic neurologic disorders, 
Hodgkin's disease, leprosy, and rheumatoid arthri-
tis. It is of interest that amyloidosis is rarely if ever 
encountered in systemic lupus erythematosus. In 
secondary amyloidosis, deposits are most promi-
nent in the kidneys, spleen, liver, and adrenals, 
and only rarely involve the heart, gastrointestinal 
tract, or musculoskeletal system. 
Primary Amyloidosis 
Although known of for many years, the primary 
type of amyloidosis and the type associated with 
plasma cell and lymphocyte neoplasms are now 
being recognized with an increased frequency 
because of the wider use of tissue biopsies and the 
routine performance of immunochemical analyses 
of serum and urine. These two types of amyloidosis 
can be considered together on the basis of biochem-
ical and clinical evidence. The amyloid substances 
deposited and the organ distribution in these forms 
appear to be identical [11-14]. In addition, it is 
now widely appreciated that an ever-increasing 
number of patients with primary amyloidosis, if 
carefully studied, are found to have homogeneous 
immunoglobulins in the serum and/or urine and 
ultimately develop morphologic and clinical evi-
dence of a plasma cell dyscrasia [11]. 
It seems possible that such an evolution may 
take place in all individuals with the primary form 
of amyloidosis, if they are followed long enough. 
Generally this type of amyloid infiltrates predomi-
nantly the tongue, heart, skeletal muscle, skin 
ligaments, and gastrointestinal tract but it can 
also involve the same organs as the secondary type. 
Such patients often come to the attention of 
physicians because of the presence of a carpal 
tunnel syndrome, and occasionally because of the 
appearance of a neuropathy, periarticular thicken-
ing, or synovial infiltration. Some of the localized 
varieties of amyloidosis may well belong to the 
primary form. 
Familial Forms 
A variety of familial forms, many with charac-
teristic geographic localizations and tissue dis-
tributions, have been described. The most preva-
lent of these appear to be the type associated with 
familial Mediterranean fever (FMF) and the Por-
tugese type. Their large number and clinical het-
erogeneity preclude a detailed description of these 
disorders [15]. 
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Amyloid Associated with Aging 
Although clinically often inapparent, small de-
posits with many of the features of amyloid can 
often be found, if carefully looked for, in the senile 
plaques of the brain and in tissues such as the 
aorta, pancreas, testes, and other endocrine 
organs. Their incidence increases with age, and it 
may be that these deposits will ultimately be 
shown to be an invariable accompaniment of 
aging. At this time, they appear to be the best 
single indicator of the aging process [16]. 
Amyloidosis of Endocrine Organs 
For reasons that will become apparent later, the 
"amyloid" often found in certain endocrine glands 
in diseases such as diabetes mellitus and medul-
lary carcinoma of the thyroid should be considered 
separately. These types of amyloidosis which are 
usually localized to a single gland are clinically 
asymptomatic and are discovered either at autopsy 
or on pathologic examination of a surgically re-
moved endocrine tumor. 
NATURE OF AMYLOID FIBRILS 
More than 95% of the amyloid substance con-
sists of the characteristic fibrils described above 
[1-4,17]. In addition, a minor component, the 
P-component, has been noted in most amyloid 
deposits [18,19]. In general, amyloid fibrils are 
composed of two major types of proteins which 
exist either singly or in combination. One of these, 
present as the major and often the sole constituent 
in amyloids of the primary and myeloma-associ-
ated types, consists of fragments of immunoglobu-
lin light chains. This group of proteins is now called 
AL (amyloid L chain)* protein and is usually, but 
not always, associated with a similar L chain 
containing immunoglobulin in the serum [12]. 
These L chain-related proteins, which range in 
molecular weight from 5,000 to 25,000 daltons, 
consist of part or all of the variable region, usually 
part of the constant region, and may sometimes 
include the entire L chain [20]. They were first 
identified and clearly implicated as major constit-
uents of some types of amyloid by Glenner and his 
collaborators on the basis of three types of studies 
[12]. Initially, limited amino acid sequence studies 
of subunits isolated from amyloid fibrils revealed 
them to be identical to the variable region of light 
chains [20,21]. Although in most instances the 
amino acid sequence was obtained for only the first 
30 to 40 residues, it seemed likely, based on peptide 
maps and molecular weights, that these proteins 
are fragments of light chains which generally also 
include part of the carboxy terminal half. This 
likelihood received support when the same inves-
* Nomenclature agreed on at a Conference on Amyloi -
dosis held in Helsinki, Findland, August 28, 1974. To b f' 
published, O. Wigelius and A. Pasternak (eds.) Academic 
Press, New York and London. 
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tigators were able to produce fibrils with the 
appearance of amyloid fibrils by proteolytic diges-
tion of some, but not all, Bence Jones proteins, 
especially those belonging to the VAl subclass 
[22,23], and by their finding that antisera to these 
amyloid subunits cross-reacted with K or A light 
chains [24] . While there can be little doubt that 
these immunoglobulin-related proteins constitute 
most if not all of the protein in this type of amyloid 
fibril, it is not yet known whether the fragments 
are synthesized as such, or if they are the result of 
degradation of an intact L chain. Although the 
latter appears more likely, the former possibility 
can be excluded only by in vitro biosynthetic 
studies. 
Amyloid fibrils from patients with the secondary 
type of amyloidosis and certain familial forms 
[13,14,25,26] as well as amyloid isolated from 
monkeys [27], ducks [27], and guinea pigs [18] 
with experimentally induced amyloidosis, consist 
primarily of another protein that is unrelated to 
any known immunoglobulin. This protein, known 
as the AA (amyloid A) protein, * generally has a 
molecular weight of 8,500 daltons, although a 
fragment half this size has been isolated from the 
fibrils of one patient with rheumatoid arthritis 
[28]. Complete amino acid sequence studies of two 
such proteins from man [25,26] and one from the 
monkey [27], and partial amino acid sequence 
studies of several other proteins from man, duck, 
guinea pig and other species, have been reported. 
These studies have revealed striking similarities, 
but have also disclosed some differences, especially 
in the carboxy terminal half of different human 
proteins, and have clearly documented the ex-
pected homologies between the human and pri-
mate and subprimate molecules. It is of interest 
that the human protein is often heterogeneous at 
the amino terminus and that several additional 
residues precede the first residue in guinea pig 
amyloid, a finding which suggests that it, too, may 
be derived from a large precursor by proteolysis 
[13,18,25]. In addition to the AA protein, varying 
quantities of immunoglobulin L chain-related pro-
teins, often polyclonal in nature, are also present in 
these amyloid fibrils [25]. 
Using antisera to this component, it has been 
possible to detect in serum an antigenically-related 
larger component known as SAA (serum A-related 
protein) * which has been purified and which 
appears to be the precursor of the tissue compo-
nent [29-31]. Radioimmunoassay has permitted 
accurate quantitation of this serum component 
and has revealed a number of interesting and 
clinically useful features which can be summarized 
as follows [31]: (1) The concentration of SAA is 
very low (less than 200 ng/ml) and remains in that 
range during the first five decades of life but 
increases significantly in the older age groups, 
often reaching levels more than 10 times greater in 
the eighth and ninth decades. (2) The concentra-
tion of SAA increases in all types of amyloidosis, 
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cancer, infections, rheumatoid arthritis, multiple 
myeloma, macroglobulinemia, lymphomas and a 
variety of other chronic illnesses, but less so in a 
small number of patients with systemic lupus 
erythematosus. As a consequence, the almost 
invariable increases noted in the sera of patients 
with amyloidosis cannot be used as a simple 
diagnostic test. (3) In acute infections, and in 
exacerbations of certain chronic diseases, the pro-
tein often behaves like an acute-phase reactant, 
quickly returning to normal levels as the disease is 
brought under control. (4) The concentration of 
SAA increases in pregnancy. In serum, the SAA 
protein exists as complexes with a molecular 
weight of 85,000 and about 170,000, apparently 
bound to serum albumin. After acid treatment, a 
fragment antigenic ally related to the AA protein 
with a molecular weight of 12,000 can be isolated 
by chromatography on Sephadex. Preliminary 
studies of this protein suggest that it shares part of 
its amino acid sequence with the AA protein 
[32-34], and that AA constitutes the aminotermi-
nal portion of SAA from which it may be derived 
by proteolysis [33,35]. 
Lest readers be left with the impression that all 
amyloid consists of one or the other of these 
molecules, they should be warned that little is 
known about the nature of some other forms of 
amyloid, such as the senile type. Furthermore, 
based on older histochemical studies [36] coupled 
with the recent demonstration that ,B-pleated sheet 
fibrils can be formed from insulin and glucagon 
[37], and the tentative identification of thyrocal-
citonin in the amyloid of medullary carcinomas of 
the thyroid [38], one must seriously consider the 
possibility that other peptides may yield fibrils 
with the properties of amyloid. The significance of 
the minor component found in most amyloid 
deposits and known as the P-component or dough-
nut, because of its characteristic morphologic 
appearance, remains unknown. This protein has a 
molecular weight of 180,000 daltons, is composed 
of 5 identical non-covalently linked subunits, and 
is antigenic ally related to an a 1 serum glycoprotein 
[18,19]. 
Although few of these advances have found 
immediate clinical application, it seems likely that 
they will soon be of value in practice. In particular, 
antisera specific for the conformational ant igens of 
the fibrils may prove useful as sensitive diagnostic 
reagents in examining biopsies. The availability of 
antisera to specific amyloid proteins may allow us 
to classify patients more accurately and perhaps to 
characterize the nature of some of the as yet 
ill-defined types of amyloids which, because of 
their diffuse distribution in small deposits , do not 
lend themselves readily to chemical analyses. For 
example, in the case of senile amyloid, preliminary 
histochemical results by Wright (1974, personal 
communication), which suggest that this type of 
amyloid is related to L chains, could receive 
definitive support by immunochemical studies. 
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PATHOGENESIS 
While of utmost interest in terms of understand-
ing and, hopefully, eventually controlling the dis-
ease successfully, studies of possible etiologic and 
pathogenetic mechanisms are so complex that they 
cannot be discussed in detail. Hence, only a few 
salient points will be mentioned. The existence of a 
plethora of models and factors which can induce 
amyloid precludes precise conclusions concerning 
pathogenesis, especially since in many instances 
apparently contradictory mechanisms have been 
implicated [14]. While the biochemical studies of 
the amyloid substance have yielded potentially 
important clues, they have fallen short of providing 
us with a clear insight into pathogenesis. Hopefully 
the application of advances in the fields of cellular 
and humoral immunity to studies of the disease 
will aid us in the next few years in unravelling the 
many questions that remain. In general, amyloido-
sis is associated with exposure to a large antigenic 
load (as is the case in the casein model , hyperim-
munized horses, and chronic infections in man). 
Recent studies indicate that the deposition of 
amyloid may be accompanied by depressed T-cell 
function [39], can be accelerated by immunosup-
pressive agents, and often accompanies naturally 
occurring immunodeficiency states [14]. Of partic-
ular interest in this regard is the recent observation 
that the SAA protein from mouse serum seems to 
diminish the amount of antibody produced in vitro 
to sheep red blood cells [40]. This finding, taken 
together with the existence of naturally occurring 
and experimental amyloid in situations where the 
immune system is overwhelmed by an antigenic 
load or where it undergoes neoplastic transforma-
tion, raises the possibility that the AA protein may 
be a substance with immunoregulatory properties, 
produced most probably by cells belonging to the 
immune system [41]. These findings suggest the 
possibility that amyloid can be stopped or is 
reversible if the stimulus is removed. Although 
some instances of regression of the disease after 
cure of the underlying condition have been re-
ported, the resistance of amyloid to phagocytosis 
and proteolysis hampers the ready removal of the 
material by the host's defense mechanisms 
[4,42-44 ]. 
One promising note has been sounded recently. 
Stimulated by the successful use of colchicine in 
aborting the febrile episodes of FMF, a disease 
often accompanied by amyloidosis, Kedar et al 
(45) have shown that colchicine can prevent the 
appearance of amyloidosis in mice given casein, a 
finding that has also been reported by Shirahama 
and Cohen [46]. Although the precise mechanisms 
of action of colchicine in this regard are unknown, 
the drug is sufficiently nontoxic to warrant a 
large-scale controlled trial in this otherwise hope-
less disease. 
CUTANEOUS AMYLOIDOSES 
Amyloidosis is of interest to dermatologists for 
three reasons. Firstly, although the skin is rarely, if 
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ever, involved in the secondary form of the disease, 
amyloid deposits occur frequently in the skin in the 
primary and myeloma-related types of the disease. 
Secondly, and probably more importantly, there 
exist several localized types of amyloidosis which 
involve only the skin and are virtually never 
associated with systemic disease. These cutaneous 
forms of amyloidosis, while often annoying to the 
patient, are quite benign. Lastly, amyloidosis is on 
occasion a late complication of certain chronic 
dermatologic conditions such as hidradenitis, sup-
purative stasis ulcers, psoriasis, lupus ery-
thematosus, dermatomyositis, basal cell carci-
noma, epidermolysis bullosa, and lepromatous lep-
rosy. Since this type of amyloidosis is identical to 
the secondary form associated with many chronic 
diseases, it will not be discussed further. All these 
types of amyloidosis are reviewed in detail in three 
papers by Brownstein and Helwig [47-49]. 
In the primary and myeloma-associated types, 
papules are the most common cutaneous lesions. 
They are usually nontender and nonpruritic. Most 
often they are skin colored or yellow and translu-
cent or waxy in appearance. They are rarely 
ulcerated, but often have a hemorrhagic compo-
nent. The face, especially the eyelids, scalp, and 
neck are most frequently involved, although on 
occasion lesions can occur also on the trunk and 
extremities. Nodules or tumors, often very large in 
size with a hemorrhagic component due to involve-
ment of the blood vessels, are sometimes seen. 
Cutaneous plaques which may impair the motion 
of the fingers , toes, and facial muscles, and may 
result in ulcerations of the skin may be present. 
Blood vessel involvement may result in purpura, 
commonly involving the face and eyelids, which is 
often brought on by minor trauma such as rubbing. 
Of lesser importance are alopecia, waxy discolora-
tion of the skin, and abnormalities of the nails such 
as crumbling, brittleness, and anonychia. In this 
type of systemic amyloidosis involving the skin, 
the amyloid deposits are seen in the walls of the 
blood vessels, especially in the peri adventitial zone 
and in the papillary corium and are associated 
with an attenuated epidermis, but a normal kera-
tin and granular layer. The epidermis is usually 
uninvolved while the connective tissue of the 
corium and the dermis are often heavily infiltrated 
by amyloid deposits. The larger deposits are some-
times infiltrated with foreign-body giant cells and 
foci of plasma cells, but generally the amyloid 
deposits are quite acellular. 
Of greater concern to the dermatologist are the 
primary localized benign cutaneous forms of amy-
loidosis, which are never associated with systemic 
involvement. The most common variant is lichen 
amyloidosis where amyloid deposits of the papil-
lary corium give rise to pruritic papules, most 
commonly on the lower extremities. The lesions are 
most frequently seen in the pretibial area but also 
on the calves, thighs, ankles, and dorsa of the feet. 
The papules are usually firm, nontender, hyperker-
atotic, and discrete. On occasion, individual 
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lesions occur in close proximity and may some-
times fuse to give verrucoid plaques. The papules 
range in size from 1 to 10 mm in diameter and vary 
in color from that of normal skin to gray or 
yellowish brown. They occur in individuals of all 
ages and may last for many years. Occasionally the 
upper extremities, shoulders, sacrum, and abdomi-
nal and chest wall may also be involved. 
In this form of localized amyloidosis, the de-
posits are limited to the dermal papillae and do not 
involve the epidermis from which they are usually 
separated by a thin layer of collagen. The epider-
mis may be thinned and the keratin layer is usually 
compact and focally thickened. The deeper cutis 
and subcutaneum are uninvolved, and, as is true of 
all types of amyloidosis, there are few if any 
inflammatory cells in the lesions. Unlike the sys-
temic types of amyloidosis where the capillary 
walls are involved, the deposits in lichen amyloido-
sis are found around the capillary wall and do not 
involve the walls of the blood vessels. Electron 
microscopy and staining with Congo red and meta-
chromatic dyes have identified the fibrils as amy-
loid, but chemical and immunochemical elucida-
tion of their precise composition remains to be 
undertaken. 
The macular form of amyloidosis is less common 
and consists of oval, poorly delineated, hyperpig-
mented patches of aggregated, grayish brown 
macules. Its distribution and pathologic features 
resemble the papular type and it may progress to 
the papular form in time. 
The third type of cutaneous amyloidosis , the 
tumefactive form, is less clearly benign since, in a 
significant number of cases, it may progress to a 
systemic form of the disease. The lesions are seen 
on the extremities, trunk, or face, involve the 
corium and subcutaneous tissue, and may affect 
the large blood vessels and cause thinning of the 
epidermis. 
Lastly, asymptomatic deposits with the staining 
characteristics of amyloid are seen in a variety of 
dermatologic conditions such as seborrheic kera-
toses, basal cell carcinomas, Bowen's disease, 
cylindromas, and pilomatrixomas. 
In considering the pathogenesis of these local-
ized forms of the disease, it is imperative to first 
establish the nature of the amyloid and the cells 
producing them. So far, there is no information as 
to whether they are associated with the AA protein, 
L chains, or if they represent a yet different type of 
protein. This association could best be determined 
with fluoresceinated antisera or by biochemical 
analyses. Then, one would have to establish that 
the deposits are locally produced and search for 
agents or stimuli which may cause a local disturb-
ance in imm une regulation that can set off the 
synthesis of the amyloid precursor. It seems possi-
ble that some as yet undefined local infectious 
agent or toxic products may initiate such a process, 
perhaps in genetically predisposed individuals. 
With currently available tools, answers to these 
questions will be soon forthcoming. 
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DISCUSSION 
Epstein: What is the doughnut molecule? 
Franklin: The doughnut, which is not a constituent of 
the amyloid fibril and generally makes up less than 5% of 
the amyloid substance, appears to be a pentamer existing 
as a 170,000 dalton serum QlI globulin whose nature and 
function remain unknown . Partial amino acid sequence 
studies by Skinner have not shed significant light on this 
question. This component has been identified in all types 
of amyloidosis and may perhaps interact in a more or less 
specific manner with the major amyloid constituents. 
Windhorst: Children with chronic granulomatous dis-
ease, other patients with chronic infections, and aged 
people have prominent intracellular deposits of a sub-
stance called lipofucsin. Do you have any information 
about a possible relationship between amyloid and this 
material? 
Franklin: I am not aware of any relation to lipofucsin. 
The intracellular identification of amyloid has proved to 
be a difficult task since many cells develop intracellular 
fibrils resembling amyloid in situations of stress. Thus , 
we assume intracellular fibrils in cells in the vicinity of 
amyloid to be amyloid , but we can't be sure . A few years 
ago we used some of our antisera to conformational 
an tigens on the fibrils to stain cells and were able to get 
fluorescence with some cells surrounding amyloid de-
posits. Obviously these studies should be pursued fur-
ther. 
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Tan: Do you think that problems encountered in 
determining the cell making AA protein might be related 
to the fact that you have an antiserum to denatured AA 
protein which cross-reacts poorly with native AA protein 
in the cell of origin? This problem is seen with antiserum 
raised against solubilized histones which reacts very well 
with solubilized histones in vitro but not with native 
histones in cell smears or tissue sections. 
Franklin: This is one possibility but not a likely one 
since these antisera react well with the native serum 
component which gives a reaction of complete identity 
with the AA protein. It seems more likely to us that either 
the protein is rapidly turned over and does not accumu-
late in the cell, or that we have not yet looked at the 
correct cell. We are currently looking at the question in 
somewhat greater detail. 
Kirkpatrick: Do nude mice have unusual susceptibil-
ity to amyloid? I ask because of your reference to 
prevention of amyloidosis with thymus hormone. Also, do 
NZB mice develop amyloidosis and is it possible to delay 
or prevent it with thymus cells? 
Franklin: Both types of animals are likely candidates. 
The results in nude mice are somewhat contradictory and 
not very striking. Amyloid has been seen in NZB mice. 
Kantor: Have you looked for homology of amyloid 
with other acute phase reactants such as C-reactive 
protein, fibrinogen , and complement? 
Franklin: The AA protein is different from C-reactive 
protein, fibrinogen , and a host of minor, known and 
unknown QlI serum globulins. With Peter Lachmann we 
have ruled out a relation to a few complement compo-
nents but we are continuing to look at this question 
further since it is obviously an attractive idea to link the 
AA protein to complement. 
Gigli: Is it possible that the doughnut and the fibrils 
seen in amyloidosis are part of the same molecule 
resembling Clq? 
Franklin: On the basis of the morphology of these 
doughnuts and their size, this possibility seems unlikely 
since the doughnuts are very large . However , as I 
mentioned before it would be attractive to implicate 
complement in these amyloid deposits and we will 
continue to look for a relation to complement in the 
future. 
